戻る Agenda
The Future of Precision Medicines: How the Regulatory Framework Keeps Up with Evolving Science
Session Chair(s)
Lucia D'Apote, DrSc, RAC
Executive Director Global Regulatory Policy
Amgen, Switzerland
This session will provide a platform for scientific exchange among the EMA, the EC DG Research and other global health authorities (e.g. FDA), patient advocates, and drug development innovators on the evolving global landscape for precision medicine
Learning Objective : • Foster discussions and education of the challenges and opportunities posed by precision medicines and learn about major EU and International initiatives • Understand learnings from Precision medicines programmes funded and authorized in the EU and experience of other Regulators
Speaker(s)
Regulator Perspective
Falk Ehmann, MD, PhD, MS
Regulatory Science and Innovation Task Force, European Medicines Agency, Netherlands
Head of Innovation and Development Accelerator
Irene Norstedt
European Commission, Belgium
Director - People Directorate, DG Research and Innovation
Antonella Cardone
Cancer Patients Europe, Belgium
Director
Christine Mayer-Nicolai, PharmD
Merck Healthcare KGaA, Germany
Vice President, Regulatory and Scientific Policy
Christian Schneider, DrMed
PharmaLex, Denmark
Head of Biopharma Excellence and Chief Medical Officer (Biopharma)